Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Eagle Pharmaceuticals, Inc. (EGRX : NSDQ)
 
 • Company Description   
Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey.

Number of Employees: 102

 
 • Price / Volume Information   
Yesterday's Closing Price: $47.07 Daily Weekly Monthly
20 Day Moving Average: 124,229 shares
Shares Outstanding: 12.70 (millions)
Market Capitalization: $597.72 (millions)
Beta: 0.68
52 Week High: $58.25
52 Week Low: $36.48
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -5.92% 2.67%
12 Week -2.73% 2.41%
Year To Date -7.56% 7.75%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
50 TICE BOULEVARD SUITE 315
-
WOODCLIFF LAKE,NJ 07677
USA
ph: 201-326-5300
fax: -
investors@eagleus.com http://www.eagleus.com
 
 • General Corporate Information   
Officers
Scott Tarriff - Chief Executive Officer; President and Director
Michael Graves - Chairman
Brian Cahill - Chief Financial Officer
Steven Ratoff - Director
Jennifer K. Simpson - Director

Peer Information
Eagle Pharmaceuticals, Inc. (BJCT)
Eagle Pharmaceuticals, Inc. (CADMQ)
Eagle Pharmaceuticals, Inc. (APNO)
Eagle Pharmaceuticals, Inc. (UPDC)
Eagle Pharmaceuticals, Inc. (IMTIQ)
Eagle Pharmaceuticals, Inc. (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 269796108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 12.70
Most Recent Split Date: (:1)
Beta: 0.68
Market Capitalization: $597.72 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $2.48 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $8.22 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 5.73
Trailing 12 Months: 16.99
PEG Ratio: -
Price Ratios
Price/Book: 2.77
Price/Cash Flow: -
Price / Sales: 2.43
EPS Growth
vs. Year Ago Period: 11,466.67%
vs. Previous Quarter: 810.42%
Sales Growth
vs. Year Ago Period: 180.91%
vs. Previous Quarter: 173.80%
ROE
03/31/22 - 18.56
12/31/21 - -4.62
09/30/21 - 2.97
ROA
03/31/22 - 13.10
12/31/21 - -3.34
09/30/21 - 2.18
Current Ratio
03/31/22 - 2.36
12/31/21 - 2.32
09/30/21 - 3.55
Quick Ratio
03/31/22 - 2.12
12/31/21 - 2.03
09/30/21 - 3.35
Operating Margin
03/31/22 - 14.56
12/31/21 - -5.03
09/30/21 - 3.14
Net Margin
03/31/22 - 14.56
12/31/21 - -5.03
09/30/21 - 3.14
Pre-Tax Margin
03/31/22 - 21.03
12/31/21 - -2.65
09/30/21 - 3.13
Book Value
03/31/22 - 17.01
12/31/21 - 13.66
09/30/21 - 14.15
Inventory Turnover
03/31/22 - 3.67
12/31/21 - 3.64
09/30/21 - 5.21
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.11
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 9.52
 

Powered by Zacks Investment Research ©